利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.019 秒)

    Methods for Use of Neural Stem Cell Compositions for Treatment of Central Nervous System Lesions
    3.
    发明申请
    Methods for Use of Neural Stem Cell Compositions for Treatment of Central Nervous System Lesions 有权
    使用神经干细胞组合物治疗中枢性神经系统损害的方法

    公开(公告)号：US20140308256A1

    公开(公告)日：2014-10-16

    申请号：US14362891

    申请日：2012-12-12

    申请人： The Regents of the University of California

    发明人： Paul Lu ,  Mark H. Tuszynski

    IPC分类号： A61K38/18 ,  A61K35/30

    CPC分类号： A61K38/185 ,  A61K35/30 ,  A61K38/18 ,  A61K2300/00

    摘要： Methods for inducing non-embryonic lesioned central nervous system neurons to survive, integrate, extend axons over long distances, induce intra-lesion ingrowth of neurons into the lesion from host tissue and form synapses in vivo. Pluripotent neural stem cells are grafted into the lesioned CNS tissue within a tissue adhesive suspension, optionally in the presence of growth factors. No modification of the neuronal regenerative inhibitory environment of the CNS is necessary.

    摘要翻译： 诱导非胚胎损伤的中枢神经系统神经元生存，整合，长距离延伸的轴突的方法，诱导神经元内的病变向内生长进入宿主组织的病变，并在体内形成突触。 多能神经干细胞可任选地在生长因子存在下移植到组织粘附性悬浮液内的病变CNS组织中。 不需要对CNS的神经元再生抑制环境进行修饰。

    Biomimetic Scaffold for Peripheral Nerve Injuries
    4.
    发明申请
    Biomimetic Scaffold for Peripheral Nerve Injuries 有权

    公开(公告)号：US20220167988A1

    公开(公告)日：2022-06-02

    申请号：US17602727

    申请日：2020-04-10

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： Mark H. Tuszynski ,  Yacov Koffler ,  Isac Lazarovits

    IPC分类号： A61B17/11

    摘要： Biomimetic scaffolds for neural tissue growth are disclosed herein which have a plurality of microchannels disposed within a sheath. Each microchannel comprises a porous wall that is formed from a biocompatible and biodegradable material. The biocompatible and biodegradable material may be polyethylene glycol) diacrylate, methacrylated gelatin, methacrylated collagen, or polycaprolactone, and combinations thereof. The biomimetic scaffolds have high open volume % enabling superior (linear and high fidelity) neural tissue growth, while minimizing inflammation near the site of implantation in vivo.

    METHODS FOR THERAPY OF NEURODEGENERATIVE DISEASE OF THE BRAIN
    7.
    发明申请
    METHODS FOR THERAPY OF NEURODEGENERATIVE DISEASE OF THE BRAIN 有权
    脑部神经病变疾病治疗方法

    公开(公告)号：US20140057974A1

    公开(公告)日：2014-02-27

    申请号：US14071572

    申请日：2013-11-04

    申请人： The Regents of the University of California

    发明人： Mark H. Tuszynski

    IPC分类号： A61K48/00

    CPC分类号： A61K48/005 ,  A61K38/185 ,  A61K48/00 ,  A61K48/0075 ,  A61K48/0083 ,  C07K14/475 ,  C12N15/86 ,  C12N15/867 ,  C12N2740/16043 ,  C12N2799/021 ,  C12N2799/027

    摘要： A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic factor), into a targeted region of the brain (such as the substantia nigra) using a lentiviral expression vector. The neurotrophin is delivered to, or within close proximity of, identified defective, diseased or damaged brain cells. The concentration of neurotrophin delivered as part of a neurotrophic composition varies from 1010 to 1015 neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives from 2.5 μl to 25 μl of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 μm of, a targeted cell, and no more than about 10 mm from another delivery site. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated.

    摘要翻译： 用于治疗哺乳动物脑中有缺陷，患病和受损神经元的特定临床方案，对于治疗神经变性疾病如帕金森病和阿尔茨海默氏病尤其有用。 通过使用慢病毒表达载体将确定浓度的重组神经营养因子（例如神经胶质细胞衍生的神经营养因子）递送至脑的靶向区域（例如黑质）来实施该方案。 神经营养蛋白被递送到或者在非常接近的识别的有缺陷的，患病的或受损的脑细胞中。 作为神经营养组合物的一部分递送的神经营养因子的浓度在编码病毒颗粒/ ml组合物流体的1010至1015个神经营养因子中变化。 每个送货站点从2.5毫升到25毫升的神经营养组合物，缓慢递送，如超过10分钟/送货地点的一段时间。 每个递送部位在目标细胞的500μm以下，距离另一个递送部位不超过约10mm。 该方法刺激靶向神经元的生长，并与正在治疗的神经变性疾病相关的功能性逆转逆转。